Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
EP-262 by Escient Pharmaceuticals for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
EP-262 is under clinical development by Escient Pharmaceuticals and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to...
Data Insights
EP-262 by Escient Pharmaceuticals for Chronic Urticaria Or Hives: Likelihood of Approval
EP-262 is under clinical development by Escient Pharmaceuticals and currently in Phase II for Chronic Urticaria Or Hives. According to...